mFOLFOX

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Locally-Advanced Rectal CancerGastroesophageal AdenocarcinomaLocally Advanced Unresectable or Metastatic Solid Tumors

48 competitors in Locally-Advanced Rectal Cancer

#DrugCompanyPhaseTrials

1

Eloxatin

Teva

Phase 3

282

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

453

Beyfortus

BeiGene

Phase 3

94

Tyvyt

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3

65

Jemperli

GGlaxo Dba Glaxosmithkline

Phase 3

46

Avastin

Roche

Phase 2

77

Camptosar

Pfizer

Phase 2

78

FOLFOX

AstraZeneca

Phase 3

29

Mfolfirinox

Incyte

Phase 3

210

Keytruda

Merck & Co.

Phase 2

2Show 29 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Biliary Tract Cancer2 trials

GEN-001 Plus Pembrolizumab for Patients With Advanced Refractory Biliary Tract Cancer

Terminated·GGenome & Company·Phase 2·NCT05998447·10 enrolled

Open-Label, Multicenter, Phase II/III Study of Combination Therapy of D07001-Softgel Capsules and Xeloda/TS-1 in Subjects With Advanced Biliary Tract Cancer After Gemcitabine and Cisplatin-Based Treatment Failure

Terminated·IInnoPharmax Inc.·Preclinical·NCT05065957·19 enrolled

Gastric Cancer2 trials

Study of Oxaliplatin, Calcium Folinate, and 5-Fluorouracil as Neoadjuvant Chemotherapy for Resectable Advanced Gastric Cancer

Unknown status·PPeking University·Phase 2·NCT00591045·263 enrolled

Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs. FLOT Plus Nivolumab in Patients With Previously Untreated Advanced or Metastatic Gastric Cancer

Completed·IInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest·Phase 2·NCT03647969·262 enrolled

Metastatic Colorectal Cancer1 trial

BIBF 1120 Versus Bevacizumab in Metastatic Colorectal Cancer

Completed·Boehringer Ingelheim·Phase 2·NCT00904839·128 enrolled

Advanced Solid Tumors1 trial

A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors

Completed·CCantargia AB·Phase 1/2·NCT05116891·40 enrolled

Locally Advanced Unresectable or Metastatic Solid Tumors1 trial

A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors

Recruiting·Innovent Biologics (Suzhou) Co. Ltd.·Phase 1·NCT05458219·470 enrolled

5 more indications

Rectal Adenocarcinoma1 trial

Short-course Radiation Followed by mFOLFOX-6 Plus COMPOUND 2055269 for Locally-advanced Rectal Adenocarcinoma

Unknown status·AAli Shamseddine·Phase 2·NCT03503630·44 enrolled

Gastrointestinal1 trial

A Study to Evaluate Immunotherapy Combinations in Participants With Gastrointestinal Malignancies

Completed·Arcus Biosciences·Phase 1·NCT03720678·44 enrolled

Locally-advanced Rectal Cancer1 trial

A Study of Total Neoadjuvant Therapy for High-risk Locally Advanced Rectal Cancer

Active, not recruiting·—·Phase 2·NCT04543695·255 enrolled

Rectal Cancer1 trial

Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer and Low Risk for Local Failure: A Randomized Phase III Trial of the German Rectal Cancer Study Group

Terminated·RRalf Hofheinz·Phase 3·NCT04495088·215 enrolled

Gastroesophageal Adenocarcinoma1 trial

- ZANGEA - Phase II Study of Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) Patients

Recruiting·IInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest·Phase 2·NCT07176312·80 enrolled

Details

Drug Info

Related News